Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952753 · ClinicalTrials.gov registry record · Phase 2
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT04952753 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 204 participants.
The verdict
NCT04952753, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.
Interventions
- DRUG Bevacizumab
- DRUG Tislelizumab
- DRUG FOLFIRI
- DRUG Modified FOLFOX6
- DRUG NIS793
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2025-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04952753
The ClinicalTrials.gov registry entry for NCT04952753 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04952753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04952753 about?
NCT04952753 is a clinical study titled "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC". The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanis...
What is the current status of trial NCT04952753?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2021-11-15. Estimated completion is 2025-01-20.
What interventions are being tested in trial NCT04952753?
The interventions under investigation include: Bevacizumab (DRUG), Tislelizumab (DRUG), FOLFIRI (DRUG), Modified FOLFOX6 (DRUG), NIS793 (DRUG).
Who is sponsoring clinical trial NCT04952753?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.